StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Spyre Therapeutics's total assets was $1.17B at Jun 30, 2026. For fiscal 2025 it was $777.78M, up 27.8% from the year before. Over ten years it grew 35.0% a year on average. The highest annual figure on record is $777.78M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$777.78M+27.8%
FY2024Dec 31, 2024$608.48M+78.0%
FY2023Dec 31, 2023$341.86M+380.5%
FY2022Dec 31, 2022$71.14M-35.3%
FY2021Dec 31, 2021$109.93M-32.0%
FY2020Dec 31, 2020$161.62M+94.3%
FY2019Dec 31, 2019$83.18M+7.0%
FY2018Dec 31, 2018$77.74M+38.6%
FY2017Dec 31, 2017$56.08M-16.4%
FY2016Dec 31, 2016$67.06M+73.5%
FY2015Dec 31, 2015$38.65M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.17B+117.7%
Q1 FY2026Mar 31, 2026$763.95M+34.1%
Q4 FY2025Dec 31, 2025$777.78M+27.8%
Q3 FY2025Sep 30, 2025$504.60M+19.8%
Q2 FY2025Jun 30, 2025$538.83M+23.6%
Q1 FY2025Mar 31, 2025$569.78M+16.9%
Q4 FY2024Dec 31, 2024$608.48M+78.0%
Q3 FY2024Sep 30, 2024$421.09M+103.2%
Q2 FY2024Jun 30, 2024$436.07M+79.1%
Q1 FY2024Mar 31, 2024$487.60M+829.6%
Q4 FY2023Dec 31, 2023$341.86M+380.5%
Q3 FY2023Sep 30, 2023$207.27M+126.4%
Q2 FY2023Jun 30, 2023$243.53M+128.2%
Q1 FY2023Mar 31, 2023$52.45M-36.9%
Q4 FY2022Dec 31, 2022$71.14M-35.3%
Q3 FY2022Sep 30, 2022$91.57M-29.1%
Q2 FY2022Jun 30, 2022$106.71M-27.4%
Q1 FY2022Mar 31, 2022$83.17M-49.2%
Q4 FY2021Dec 31, 2021$109.93M-32.0%
Q3 FY2021Sep 30, 2021$129.06M-17.1%
Q2 FY2021Jun 30, 2021$146.98M-15.0%
Q1 FY2021Mar 31, 2021$163.61M+152.6%
Q4 FY2020Dec 31, 2020$161.62M+94.3%
Q3 FY2020Sep 30, 2020$155.63M+55.5%
Q2 FY2020Jun 30, 2020$172.91M+47.2%
Q1 FY2020Mar 31, 2020$64.78M-49.6%
Q4 FY2019Dec 31, 2019$83.18M+7.0%
Q3 FY2019Sep 30, 2019$100.10M+40.4%
Q2 FY2019Jun 30, 2019$117.49M+47.4%
Q1 FY2019Mar 31, 2019$128.52M+158.1%
Q4 FY2018Dec 31, 2018$77.74M+38.6%
Q3 FY2018Sep 30, 2018$71.28M+17.8%
Q2 FY2018Jun 30, 2018$79.71M+18.7%
Q1 FY2018Mar 31, 2018$49.79M-18.7%
Q4 FY2017Dec 31, 2017$56.08M-16.4%
Q3 FY2017Sep 30, 2017$60.50M-16.0%
Q2 FY2017Jun 30, 2017$67.14M–
Q1 FY2017Mar 31, 2017$61.27M–
Q4 FY2016Dec 31, 2016$67.06M–
Q3 FY2016Sep 30, 2016$72.06M–

More Spyre Therapeutics figures

See a number that looks wrong?